Protalix BioTherapeutics, Inc. 8-K

What Happened Protalix BioTherapeutics, Inc. filed a Current Report on Form 8‑K on May 21, 2026 (Item 7.01, Regulation FD Disclosure) to announce that it posted a corporate presentation to its website. The May 2026 corporate presentation is furnished as Exhibit 99.1 to the 8‑K. The filing is signed by Dror Bashan, President and Chief Executive Officer.

Key Details

• Filing date: May 21, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Disclosure: May 2026 Corporate Presentation furnished as Exhibit 99.1.
• Company official: Signed by Dror Bashan, President & CEO.
• The report primarily notifies investors of the public posting; no other material financial results or corporate actions were reported in this filing.

Why It Matters This 8‑K informs investors that Protalix has made its latest corporate presentation publicly available, ensuring broad, simultaneous disclosure under Regulation FD. Investors and analysts should review the posted presentation on Protalix’s website for any updates on strategy, pipeline, corporate developments, or financial context contained within the slides.